Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

Shares in WuXi Biologics and WuXi AppTec have tracked ... aid for Palestine – may well not make it through the legislative process ahead of the Presidential elections in November.

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict business ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...